Cancer Research

Norwegian Research Finds a 16% Drop in Cancer Rates Later in Life Among Those Taking Blood Thinners

Are You Taking Blood Thinners? Research Shows Your Risk for Cancer is Lower
Are You Taking Blood Thinners? Research Shows Your Risk for Cancer is Lower.

Blood thinners such as Warfarin are prescribed for millions of people around the world to control a range of cardiovascular problems. Based on the results of a recent study, the drugs may also reduce the risk of cancer, which could have future implications for cancer treatment.

A Surprising Weapon in the Battle Against Cancer

The study, recently published in JAMA Internal Medicine, involved 1.25 million people over the age of 50 in Norway. Researchers at the University of Bergen found that those who took Warfarin were 16 percent less likely to develop cancer than those who didn’t.

Benefits were even more pronounced for three of the most common forms of cancer. Prostate cancer had the highest risk reduction at 31 percent, followed by lung cancer at 20 percent and breast cancer at 10 percent.

The good news doesn’t end there. Patients taking Warfarin for atrial fibrillation, an abnormal heart rhythm, saw a 29 percent reduction in risk for bowel cancer.

Blood Thinners: A Form of Immunotherapy?

At this point, researchers are unclear how Warfarin affects the risk of cancer. They believe that the drugs may inhibit the signaling power of cancer cells, leaving them vulnerable to attack from the body’s immune system.

Despite the promising results, medical experts warn against self-medicating with Warfarin. The drug can have serious side effects, so it should always be taken under a doctor’s supervision.

Personalized Cancer Treatment at Issels®

Our cancer treatment programs harness the power of your own immune system to fight the disease. Contact us to learn more about cancer vaccines and other programs designed to meet your specific needs.

Cancer Research, Cancer Treatment, Uncategorized

New Device Helps to Accurately Detect Cancer in Tissue Biopsies

New Advances in Early Cancer Detection
New Advances in Early Cancer Detection

One of the biggest roadblocks to successful cancer treatment is the difficulty of differentiating between healthy and diseased tissue. Cancer immunotherapy helps to address this problem, and researchers have announced development of a new device that may also improve outcomes.

Removing Cancer While Sparing Healthy Tissue

Surgery is a primary tool in the diagnosis and treatment of cancer, but there’s a risk that some of the cancerous tissue may be left behind. Surgeons sometimes use cryosection, in which a frozen tissue sample is evaluated by a pathologist, but the method is time-consuming and not always accurate.

A study published in Science Translational Medicine reveals how a team of researchers in Texas created the MasSpec Pen to detect cancer in human tissue. This device uses the dysfunctional metabolism of cancer cells to differentiate them from normal cells.

Identifying Cancerous Cells Within Seconds

Once a molecular fingerprint has been drawn, the cells are analyzed using software that has been “trained” by processing hundreds of healthy and cancerous human tissue samples. Within 10 seconds, the sample is flagged as “Normal” or “Cancer.”

The research team tested 253 samples of both normal and cancerous tissue with an accuracy rate of more than 96 percent. When the device was tested on mice, it again proved accurate without causing damage to healthy tissue. Testing in human cancer surgeries is expected to begin in 2018.

Cancer Immunotherapy at Issels®: A Personalized Treatment Program

No two cases of cancer are identical. At Issels®, we create a cancer immunotherapy program based on your specific needs. Contact us for more information.

Cancer Research, Cancer Treatment, Uncategorized

Smoking May Actually Prime Lung Cells for Cancer

Cancer Research News
Cancer Research News

The link between cigarette smoking and increased risk of lung cancer is well-established. Recent studies are giving researchers more insight into the causes of the connection as well as possible methods of treatment.

What Causes Genetic Abnormalities?

Gene behavior is driven by DNA code, but it can also be affected by other external factors. These events, such as those brought on by exposure to cigarette smoke, are known as epigenetic changes.

Researchers at Johns Hopkins Kimmel Cancer Center in Baltimore grew human bronchial cells, the same type that line airways in the lungs, and bathed them daily with a liquid form of cigarette smoke. This procedure went on for 15 months, making it the equivalent of smoking one to two packs of cigarettes a day for 20 to 30 years.

How Smoking “Primes” Cells for DNA Damage

After only 10 days, the smoke-exposed cells sustained more DNA damage than unexposed cells. Over the next three months, the exposed cells showed a significant increase in EZH2, which is a hormone that silences genes.

EZH2 is also a precursor to methylation, in which tiny methyl groups are added to the start of a gene’s DNA code. As a result, tumor suppression genes are silenced and thereby unable to prevent the uncontrolled cell growth of cancer. Smokers who quit show a lower level of methylation, which can decrease their risk of cancer.

Integrative Cancer Immunotherapy Treatment at Issels®

Our cancer immunotherapy programs incorporate gene-targeted therapies based on a patient’s individual needs. Contact us for more information about our decades of success initiating long-term remission with our innovative cancer immunotherapy treatments.

 

Alternative Cancer Treatment, Cancer Treatment, Immuno-Oncology, Immunotherapy, Uncategorized

Is the Cost of R&D for Cancer Medications Overstated?

1 Comment
Are Costs Overstated for Cancer Research?
Are Costs Overstated for Cancer Medication Research?

Significant research and development (R&D) costs are often the main reason cited for steep prices on cancer treatments. Surprisingly, a study centered on 10 new cancer drugs suggests that these costs may have been greatly overstated.

The True Costs of Cancer Treatment R&D?

Results of the study, which was recently published in JAMA Internal Medicine, determined that the R&D process for a new cancer drug usually spans seven years, with an average total cost between $648 million and $794 million.

On its face, the numbers are huge, but relatively small compared to the yardstick used by pharmaceutical companies. Their measure is the staggering figure of $2.7 billion per drug, which was determined by a Tufts University study in 2016.

Cost vs. Benefit

Even more revealing was the assessment of sales generated by the 10 drugs evaluated in the study. After an average of four years on the market, the drugs had a combined total of $67 billion in revenue, which is seven times more than the aggregate of the R&D costs.

As expected, members of the pharmaceutical industry are taking exception with the report. Dr. J. Leonard Lichtenfeld, deputy chief medical officer of the American Cancer Society, took no official position but felt that the study would prompt wider discussion on the issue.

Integrative Cancer Immunotherapy Programs from Issels®

While cancer immunotherapy is a hot topic in the medical community, Issels® has been successfully using non-toxic treatments such as cancer vaccines for decades. Contact us for more information about our cancer centers in Santa Barbara, CA and Tijuana, Mexico.

Cancer Research, Uncategorized

University of California Creates a Cancer Consortium for Research

1 Comment
Cancer Consortium Conference
Cancer Consortium Research Conference

There’s power in numbers, and the University of California is leveraging that concept to fight the battle against cancer. In September, the school announced that its five academic cancer centers are aligning to form a cancer research consortium.

Strength Through Teamwork

The partnership is made up of UC branches in Davis, Irvine, San Francisco, San Diego and Los Angeles. UC officials and researchers hope that the new consortium, believed to be the largest ever formed by a U.S. public university system, will enable larger clinical trials of cancer immunotherapy and other treatments across a wider spectrum.

The announcement has particular resonance in California, where cancer is on the verge of overtaking heart disease as the leading cause of death. It also has personal meaning for UC President Janet Napolitano, who was diagnosed with cancer in 2000 and again in 2016.

Cancer Research at the University of California

Currently, the five UC cancer centers treat 16 percent of cancer patients in California, with nearly half of them in late-stage cancer. In addition, the centers have administered more than 1,600 clinical trials over the last year, moving the top therapies along the road to FDA approval.

According to Paula Aspiazu of the American Cancer Society, their organization provides $23 million in funding to the UC system. Aspiazu pointed out that the consortium means each center can now draw data from a larger pool rather than only their own specific group.

State-of-the-Art Cancer Immunotherapy at Issels®

Our cancer immunotherapy programs aren’t simply clinical trials. Contact us to learn how patients with late-stage cancer of all forms have achieved long-term remission at Issels®.

Alternative Cancer Treatment, Cancer Treatment, Living with Cancer, Stage Four Cancer Treatment, Uncategorized

More Medications Focus on Immunotherapy to Combat Lung Cancer

1 Comment
Join Us in the Fight Against Lung Cancer
Join Us in the Fight Against Lung Cancer

As immunotherapy becomes an increasingly significant factor in cancer treatment, major pharmaceutical companies are scrambling to get their own piece of the pie. One of the minor players has seemingly vaulted ahead of the competition by targeting a niche segment of the market that had been largely overlooked.

AstraZeneca’s Second Chance for Success

AstraZeneca made a bold but risky move by going all-in on their pair of immuno-oncology drugs (IO) designed to treat lung cancer. The combo turned out to be a major failure, which seemed to spell doom for the company.

Surprisingly, trial results presented at a recent European cancer conference seem to indicate a turnaround for Astra’s fortunes. Imfinzi, the lead drug in their IO duo, has proven to be more successful in treating patients with mid-stage lung cancer.

Blazing New Trails in Cancer Treatment

Most pharmaceutical companies concentrate on late-stage lung cancer, which represents a greater share of the market. Focusing on the under-served mid-stage lung cancer segment gives Astra the chance for modest but substantial sales growth outside the shadow of competitors such as industry leader Merck & Co.

According to experts, pharmaceutical industries are so fearful of losing business that they tend to stay in the same lane as their competitors. The experts believe that a company has a greater chance of success as a pioneer in an area with little activity.

Issels®: Leading the Way in Personalized Cancer Treatment

While immunotherapy is a seemingly new development in cancer treatment, we have been using cancer vaccines and other non-toxic protocols for decades. Contact us for more information about our individually tailored treatment programs.

Individualized Cancer Treatment